Cargando…
Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is also clear that a subset of this population has elevated blood eosinophils. In addition to clearly responding better to inhaled corticosteroids, it is also p...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689550/ https://www.ncbi.nlm.nih.gov/pubmed/31496677 http://dx.doi.org/10.2147/COPD.S162781 |
_version_ | 1783443041223180288 |
---|---|
author | Mkorombindo, Takudzwa Dransfield, Mark T |
author_facet | Mkorombindo, Takudzwa Dransfield, Mark T |
author_sort | Mkorombindo, Takudzwa |
collection | PubMed |
description | Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is also clear that a subset of this population has elevated blood eosinophils. In addition to clearly responding better to inhaled corticosteroids, it is also possible that this subgroup may benefit from biologic treatments targeting eosinophilic inflammation. Mepolizumab, a humanized monoclonal antibody against interleukin-5 (IL-5), may have a therapeutic effect in a subgroup of patients with COPD and eosinophilic airway inflammation. In this review, we discuss the biologic rationale for mepolizumab targeting IL-5 in eosinophilic COPD as well as the results of recently published clinical trials. |
format | Online Article Text |
id | pubmed-6689550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66895502019-09-06 Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease Mkorombindo, Takudzwa Dransfield, Mark T Int J Chron Obstruct Pulmon Dis Review Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is also clear that a subset of this population has elevated blood eosinophils. In addition to clearly responding better to inhaled corticosteroids, it is also possible that this subgroup may benefit from biologic treatments targeting eosinophilic inflammation. Mepolizumab, a humanized monoclonal antibody against interleukin-5 (IL-5), may have a therapeutic effect in a subgroup of patients with COPD and eosinophilic airway inflammation. In this review, we discuss the biologic rationale for mepolizumab targeting IL-5 in eosinophilic COPD as well as the results of recently published clinical trials. Dove 2019-08-07 /pmc/articles/PMC6689550/ /pubmed/31496677 http://dx.doi.org/10.2147/COPD.S162781 Text en © 2019 Mkorombindo and Dransfield. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Mkorombindo, Takudzwa Dransfield, Mark T Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease |
title | Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease |
title_full | Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease |
title_fullStr | Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease |
title_full_unstemmed | Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease |
title_short | Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease |
title_sort | mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689550/ https://www.ncbi.nlm.nih.gov/pubmed/31496677 http://dx.doi.org/10.2147/COPD.S162781 |
work_keys_str_mv | AT mkorombindotakudzwa mepolizumabinthetreatmentofeosinophilicchronicobstructivepulmonarydisease AT dransfieldmarkt mepolizumabinthetreatmentofeosinophilicchronicobstructivepulmonarydisease |